Related Experiment Videos
[Gene therapy for arteriosclerotic diseases]
M Aoki1, R Morishita, T Ogihara
1Department of Geriatric Medicine, Osaka University Medical School.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|February 24, 2001
Summary
Gene therapy offers new cardiovascular treatments for restenosis and ischemic diseases. Clinical trials using VEGF and E2F decoy show promise, with HGF-based angiogenesis a potential future therapy.
Area of Science:
- Molecular biology and cardiovascular medicine.
- Focus on gene therapy for complex adult diseases.
Context:
- Cardiovascular diseases like restenosis and ischemic conditions are widespread.
- Gene therapy has emerged as a promising treatment strategy.
Purpose:
- To explore the potential of gene therapy, including VEGF and E2F decoy, for cardiovascular diseases.
- To investigate hepatocyte growth factor (HGF) as a novel endothelial growth factor for therapeutic angiogenesis.
Summary:
- Clinical trials using Vascular Endothelial Growth Factor (VEGF) for restenosis and angina have demonstrated beneficial effects.
- A clinical trial using E2F decoy for restenosis post-angioplasty commenced in April 2000.
- Hepatocyte growth factor (HGF) is being explored for its potential in therapeutic angiogenesis to treat severe ischemic diseases.
Impact:
- Gene therapy, including VEGF and E2F decoy, shows potential for treating restenosis and angina.
- HGF-based therapeutic angiogenesis may offer a novel treatment for severe ischemic diseases, improving cardiovascular health.